Clinical Trials Browser

Phase 1/2 × Recruiting × Trastuzumab × Clear all

NCT06324357 2026-03-18

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

81 enrolled

Breast

Breast Neoplasms

NCT07007559 2026-02-03

ASPEN-09

Phase 1/2 Recruiting

80 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

48 enrolled

Breast

Cancer Related Cognitive Decline

NCT07040059 2025-06-26

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 1/2 Recruiting

18 enrolled

Gastrointestinal

HER 2 Positive Gastric Cancer

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05785741 2025-03-05

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

1,000 enrolled

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05640830 2024-11-26

TREAZURE

Phase 1/2 Recruiting

47 enrolled

Gastrointestinal

HER2-positive Advanced Gastric Cancer

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1/2 Recruiting

90 enrolled

Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT04092673 2024-05-21

Zotatifin

Phase 1/2 Recruiting

30 enrolled

Other solid neoplasm

Solid Tumor, Adult